"YM Biosciences initiated with a Buy at Collins Stewart
Wow, knock me over with a feather. Was this a 12-month target? I would be pleased as punch if YMI got up to $3 by December.
The great unknown with YMI is whether they go it alone or partner up. Conduct the Phase 3 trial by themselves or bring in some heavy hitters to clear the path toward FDA approval?
I don't think YMI is 'buyout eligible' until they get through the Phase 3 trial, lock the database, analyze, and release results. Even then, a potential buyer may want to wait until CYT387 is approved by the FDA. Such a long road ahead of us.